Amir Friedman is a pain physician, physician-scientist, and investigator with 25 years of clinical experience and more than 10,000 patients treated. He trained in surgery, anesthesiology, critical care, and pain medicine at the University of Southern California and the University of California, Los Angeles.
His work focuses on chronic pain, neuromodulation, regenerative medicine, longevity, men's health, and emerging approaches to chronic disease. He writes about neuroscience, AI-enabled medicine, and the challenge of translating innovation into meaningful patient care.
Friedman also applies his experience in complex chronic illness and care delivery through his work with Broadway Community Care Centers in California, advancing integrated behavioral health care models designed to improve access, coordination, and outcomes for underserved communities. He can be found on LinkedIn.
Systematic review data puts the prevalence of central sensitization features among knee osteoarthritis patients at approximately 36 percent by validated instrument. More than one in three patients carrying an orthopedic diagnosis you trust, presenting with pain that structural intervention may only partially address. The joint pathology on the imaging is real. The dominant pain mechanism is incompletely characterized.
In my last piece, I argued that glucagon-like peptide-1 (GLP-1) pharmacology and neurotechnology …
Read more…
The nociplastic pain question new pain therapies avoid
Fifty million Americans wake up in chronic pain every day. Not soreness. Not the dull ache of a hard week. Pain that has dismantled careers, ended marriages, and driven people, my patients, over 25 years, to suicide, overdose, and a slow erasure of self. I trained at USC and UCLA, spent three decades in interventional pain management, and I can tell you with clinical certainty: the system we built to …
Read more…
GLP-1s and neurotech are colliding over chronic pain
